Want to see IMVT full AI Analyst Report?
IMVT Stock Chart & Stats
$43.82
$0.83(2.11%)
At close: 4:00 PM EDT
$43.82
$0.83(2.11%)
Day’s Range― - ―
52-Week Range$14.58 - $45.42
Previous CloseN/A
Volume269.94K
Average Volume (3M)1.06M
Market Cap
$8.43B
Enterprise Value$7.12K
Total Cash (Recent Filing)$797.80M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Oct 30, 2026EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.82
Shares Outstanding206,552,690
10 Day Avg. Volume1,117,469
30 Day Avg. Volume1,056,026
Financial Highlights & Ratios
PEG Ratio-6.12
Price to Book (P/B)5.31
Price to Sales (P/S)0.00
P/FCF Ratio-11.12
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$49.70Price Target Upside13.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.87
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet With Minimal LeverageMinimal leverage reduces refinancing and interest-rate risk, while substantial equity and assets provide financial flexibility to fund clinical development and absorb setbacks without immediate dependence on debt markets.
Settlement Materially Strengthens LiquidityThe settlement provides a substantial liquidity buffer that can support multiple clinical programs, regulatory activities and commercialization investment, extending operational flexibility while reducing near-term financing dependence.
Broad Pipeline With Multiple Development And Launch CatalystsA diversified pipeline and recurring clinical milestones create multiple opportunities to convert research investment into approved products and revenue, reducing reliance on any single indication over the medium term.
Bears Say
Pre-revenue Business ModelThe absence of commercial product revenue leaves the company dependent on clinical success, regulatory approvals and external funding sources, limiting earnings visibility until launches generate sustainable product sales.
Very High And Increasing Cash BurnLarge operating cash outflows and worsening burn increase the resources required to sustain development. Even with strong liquidity, prolonged spending could reduce financial flexibility before commercial revenues scale.
Clinical Execution And Trial-power RiskVariability in placebo response, patient populations and disease biology can weaken statistical power or limit data interpretation, creating durable risk to approval timelines, pipeline value and future commercialization plans.
Immunovant News
IMVT FAQ
What was Immunovant’s price range in the past 12 months?
Immunovant lowest stock price was $14.58 and its highest was $45.42 in the past 12 months.
What is Immunovant’s market cap?
Immunovant’s market cap is $8.43B.
When is Immunovant’s upcoming earnings report date?
Immunovant’s upcoming earnings report date is Oct 30, 2026 which is in 58 days.
How were Immunovant’s earnings last quarter?
Immunovant released its earnings results on Aug 06, 2026. The company reported -$0.75 earnings per share for the quarter, missing the consensus estimate of -$0.629 by -$0.121.
Is Immunovant overvalued?
According to Wall Street analysts Immunovant’s price is currently Undervalued.
Does Immunovant pay dividends?
Immunovant does not currently pay dividends.
What is Immunovant’s EPS estimate?
Immunovant’s EPS estimate is -0.74.
How many shares outstanding does Immunovant have?
Immunovant has 206,552,690 shares outstanding.
What happened to Immunovant’s price movement after its last earnings report?
Immunovant reported an EPS of -$0.75 in its last earnings report, missing expectations of -$0.629. Following the earnings report the stock price went up 1.171%.
Which hedge fund is a major shareholder of Immunovant?
Currently, no hedge funds are holding shares in IMVT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunovant Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.70 (13.42% Upside)
$49.70 (13.42% Upside)
Blogger Sentiment
Bullish
IMVT Sentiment 71%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Increased
By 3.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $11.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
171.61%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
28.88%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Immunovant
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
IMVT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial near-term and medium-term upside: a large multipart settlement that materially increases liquidity, an active and well-funded pipeline with multiple imminent readouts and a potential approval/launch for brexpiprazole in dermatomyositis, successful enrollments in registrational studies, and ongoing shareholder capital returns. These positives were balanced against recognized clinical and operational risks—placebo variability, translation risk for PH-ILD, JAK-class safety perceptions, geographic variability in trials, and continued high R&D and G&A spend. On balance, management presents confident execution and a strong catalyst calendar that outweigh the disclosed risks.View all IMVT earnings summariesIMVT Stock 12 Month Forecast
Average Price Target
$49.70
▲(13.42% Upside)
Technical Analysis
TG Therapeutics
―
Viridian Therapeutics
―
Aurinia Pharmaceuticals
―
Protagonist Therapeutics
―
Kymera Therapeutics
―
Ownership Overview
56.19% Insiders
11.94% Mutual Funds
4.30% Other Institutional Investors
20.00% Public Companies and
Individual Investors